Lifecare Crescita futura

Future criteri di controllo 1/6

Si prevede che gli utili di Lifecare diminuiranno a 13.5% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 8.9% all'anno. Si prevede che l'EPS diminuirà di 8.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà -98.1% in 3 anni.

Informazioni chiave

-13.5%

Tasso di crescita degli utili

-8.3%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	19.5%
Tasso di crescita dei ricavi	8.9%
Rendimento futuro del capitale proprio	-85.3%
Copertura analitica	Low
Ultimo aggiornamento	17 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We Think Lifecare (OB:LIFE) Can Afford To Drive Business Growth

Sep 13

We're Interested To See How Lifecare (OB:LIFE) Uses Its Cash Hoard To Grow

Apr 30

Previsioni di crescita degli utili e dei ricavi

OB:LIFE - Stime future degli analisti e dati finanziari passati (NOK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	14	-71	-78	-65	1
12/31/2025	7	-65	-72	-60	1
12/31/2024	1	-57	-56	-48	1
6/30/2024	16	-50	-46	-40	N/A
3/31/2024	11	-42	-41	-41	N/A
12/31/2023	13	-35	-37	-36	N/A
9/30/2023	13	-33	-43	-42	N/A
6/30/2023	17	-27	-34	-33	N/A
3/31/2023	23	-21	-28	-27	N/A
12/31/2022	22	-17	-24	-18	N/A
9/30/2022	17	-13	N/A	N/A	N/A
6/30/2022	10	-17	-28	-16	N/A
3/31/2022	4	-18	-25	-13	N/A
12/31/2021	2	-16	-21	-14	N/A
9/30/2021	N/A	-10	N/A	N/A	N/A
6/30/2021	5	-6	N/A	N/A	N/A
3/31/2021	5	-4	N/A	N/A	N/A
12/31/2020	5	-3	-3	-3	N/A
9/30/2020	0	-5	N/A	N/A	N/A
6/30/2020	0	-6	N/A	N/A	N/A
3/31/2020	0	-6	N/A	N/A	N/A
12/31/2019	N/A	-7	-7	-7	N/A
9/30/2019	0	-8	N/A	N/A	N/A
6/30/2019	0	-10	N/A	N/A	N/A
3/31/2019	0	-9	N/A	N/A	N/A
12/31/2018	N/A	-9	N/A	N/A	N/A
9/30/2018	0	-6	N/A	N/A	N/A
6/30/2018	0	-3	N/A	N/A	N/A
3/31/2018	0	-3	N/A	N/A	N/A
12/31/2017	N/A	-3	N/A	N/A	N/A
12/31/2016	N/A	-5	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che LIFE rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che LIFE rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che LIFE rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di LIFE ( 8.9% all'anno) crescerà più rapidamente del mercato Norwegian ( 1.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di LIFE ( 8.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che LIFE non sarà più redditizia tra 3 anni.

Lifecare Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 31% to kr37.50

Price target decreased by 20% to kr47.00

Recent updates

Price target decreased by 31% to kr37.50

Lifecare ASA Announces Biopsies and Bacteriological Existing Implant

Lifecare AS has filed a Follow-on Equity Offering in the amount of NOK 20 million.

Price target decreased by 20% to kr47.00

New major risk - Market cap size

Lifecare AS (OB:LIFE) commences an Equity Buyback Plan, under the authorization approved on September 17, 2024.

We Think Lifecare (OB:LIFE) Can Afford To Drive Business Growth

Lifecare AS Announces Successful Completion of the First Veterinary Patient of the Life Life Trial

New major risk - Shareholder dilution

Lifecare AS has completed a Follow-on Equity Offering in the amount of NOK 90 million.

Lifecare AS Files Application for a New Patent

Lifecare AS Announces Successful Pilot Production

Lifecare AS has filed a Follow-on Equity Offering in the amount of NOK 90 million.

Full year 2023 earnings released: kr0.29 loss per share (vs kr0.17 loss in FY 2022)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.15 loss in FY 2022)

Lifecare AS Appoints Renete Kaarvik as Chief Financial Officer, Effective 1 Mai 2024

Lifecare AS Announces Appointment of Tony James to Its Scientific Advisory Board

Lifecare AS, Annual General Meeting, Apr 30, 2024

New minor risk - Shareholder dilution

Lifecare AS Announces the Norwegian Food Safety Authority Receives Approval to Start LFC-SEN-002

Lifecare AS has completed a Follow-on Equity Offering in the amount of NOK 42.5 million.

New major risk - Financial position

Lifecare AS to Report Q1, 2023 Results on May 10, 2023

No independent directors

Lifecare AS Announces Interim Data Analysis of the First In-Human Study

Lifecare as Initiates Clinical Studies of the Smallest Glucose Sensor in the Worldr People Diagnosed with Diabeabetes

Chief Executive Officer recently bought kr75k worth of stock

No independent directors

Lifecare AS (OB:LIFE) signed a term sheet agreement to acquire PFÜTZNER Science & Health Institute GmbH for €1.18 million.

Lifecare AS (OB:LIFE) acquired Cantimed Ug (Haftungsbeschrsnkt) from NanoScale Systems Gmbh for €0.65 million.

Chairman of the Board Christian Hysing-Dahl has left the company

We're Interested To See How Lifecare (OB:LIFE) Uses Its Cash Hoard To Grow

Lifecare AS to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day high: kr6.40

New 90-day low: kr3.62

Lifecare AS Announces Board Appointments

New 90-day low: kr4.00

Lifecare Receives EUR 3.9 Million from the EU Commission for Development of Bionic Invisible Pancreas to Forgetdiabetes

New 90-day high: kr7.00

Chief Scientific Officer recently sold kr270k worth of stock

Lifecare Appoints Joacim Holter as CEO

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita